Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Cellular Uptake of Dietary Flavonoid Quercetin 4′-β-Glucoside by Sodium-Dependent Glucose Transporter SGLT1

Richard A. Walgren, Jiann-Trzuo Lin, Rolf K.-H. Kinne and Thomas Walle
Journal of Pharmacology and Experimental Therapeutics September 2000, 294 (3) 837-843;
Richard A. Walgren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiann-Trzuo Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolf K.-H. Kinne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Walle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Although it has been suggested that the intestinal glucose transporter may actively absorb dietary flavonoid glucosides, there is a lack of direct evidence for their transport by this system. In fact, our previous studies with the human Caco-2 cell model of intestinal absorption demonstrated that a major dietary flavonoid, quercetin 4′-β-glucoside, is effluxed by apically expressed multidrug resistance-associated protein-2, potentially masking evidence for active absorption. The objective of this study was to test the hypothesis that quercetin 4′-β-glucoside is a substrate for the intestinal sodium-dependent d-glucose cotransporter SGLT1. Cellular uptake of quercetin 4′-β-glucoside was examined with Caco-2 cells and SGLT1 stably transfected Chinese hamster ovary cells (G6D3 cells). Although quercetin 4′-β-glucoside is not absorbed across Caco-2 cell monolayers, examination of the cells by indirect fluorescent microscopy as well as by HPLC analysis of cellular content revealed cellular accumulation of this glucoside after apical loading. Consistent with previous observations, the accumulation of quercetin 4′-β-glucoside in both Caco-2 and G6D3 cells was markedly enhanced in the presence of multidrug resistance-associated protein inhibition. Uptake of quercetin 4′-β-glucoside was greater in SGLT1-transfected cells than in parental Chinese hamster ovary cells. Uptake of the glucoside by Caco-2 and G6D3 cells was sodium-dependent and was inhibited by the monovalent ionophore nystatin. In both Caco-2 and G6D3 cells, quercetin 4′-β-glucoside uptake was inhibited by 30 mM glucose and 0.5 mM phloridzin. These results demonstrate for the first time that quercetin 4′-β-glucoside is transported by SGLT1 across the apical membrane of enterocytes.

An ever-increasing body of evidence suggests that dietary flavonoids are beneficial to human health and can result in significant reductions both in the risk of developing certain cancers and in the risk of mortality from coronary heart disease and stroke through antiproliferative, antioxidant, and other mechanisms (for review, seeWalgren et al., 2000). However, a major hurdle in linking in vitro and in vivo findings has been generating evidence for oral bioavailability of the flavonoids. Estimates from human studies have indicated that the dietary flavonoids display poor and variable bioavailability (Gugler et al., 1975; Hollman et al., 1995, 1997; Manach et al., 1998; Aziz et al., 1999). In part, the observed variability is a result of the complexity of the in vivo system, which involves limited absorption as well as extensive metabolism and degradation with significant losses attributable to the intestinal microflora. An additional factor is the relative absence of molecularly specific methodologies for analysis of the various forms of the flavonoids in this complex system.

We have used the human Caco-2 cell model of intestinal absorption (Artursson and Karlsson, 1991; Yee, 1997), together with molecularly specific analysis, in an attempt to better understand the extent of and the mechanisms governing flavonoid absorption. In particular, we have focused on the most prevalent flavonoid in the Western diet, quercetin (Hertog et al., 1993). With this model, we have previously shown that quercetin aglycone is capable of crossing the intestinal epithelium, but that its major dietary form, quercetin 4′-β-glucoside, is not absorbed (Walgren et al., 1998). This latter finding was surprising because it has been previously suggested that the quercetin glucosides are absorbed within the intestine by the active glucose transporter SGLT1 (Hollman et al., 1995). Subsequently, we demonstrated that quercetin 4′-β-glucoside is effluxed from Caco-2 cell monolayers by the apically expressed multidrug resistance-associated protein MRP2 (Walgren et al., 2000).

Despite a lack of direct evidence for absorptive transport of flavonoid glucosides, work by Gee et al. (1998) supports an interaction of quercetin glucosides with the intestinal glucose transporters. In our previous studies, the activity of MRP2 could have masked evidence for SGLT1-dependent absorption. In this study, we have directly tested the hypothesis that quercetin 4′-β-glucoside is a substrate for the intestinal active glucose transporter by examining transport of this glucoside across the apical membrane of Caco-2 cells, which express human SGLT1 (Blais et al., 1987). In addition, we have examined transport of this glucoside in Chinese hamster ovary (CHO) cells stably transfected with rabbit SGLT1 (G6D3 cells; Lin et al., 1998) and compared it with transport in parental CHO cells.

Materials and Methods

MK-571 was a generous gift from A. W. Ford-Hutchinson, Merck-Frosst Center for Therapeutic Research, Pointe Claire-Dorval, Quebec, Canada. Dulbecco's PBS with 0.1 g l−1 calcium chloride was purchased from Life Technologies (Grand Island, NY). Quercetin 3-O-sulfate potassium salt was purchased from Extrasynthèse (Genay, France). Quercetin 4′-β-glucoside was isolated from the red onion as described previously (Walgren et al., 1998). Except where noted, all other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).

Cell Cultures.

Caco-2 cells obtained from American Type Culture Collection (Rockville, MD) were cultured in Eagle's minimum essential medium (MEM) (Cellgro; Mediatech, Herndon, VA) supplemented with 1% MEM nonessential amino acids (Mediatech), 10% fetal bovine serum (Summit Biotechnology, Fort Collins, CO), 100 U ml−1 penicillin, and 0.1 mg ml−1 streptomycin (Sigma Chemical Co.) and were grown in a humidified atmosphere of 5% CO2 at 37°C. Cells were subcultured at 80% confluence.

Parental CHO cells (CHO-K1) and SGLT1-transfected G6D3 cells were cultured in Dulbecco's modified Eagle's medium containing 1 mM sodium pyruvate and 2 mM l-glutamine supplemented with 10% fetal calf serum, 1% MEM nonessential amino acids, 100 U ml−1 penicillin, 0.1 mg ml−1 streptomycin, and 25 μM β-mercaptoethanol, and grown in a humidified atmosphere of 7.5% CO2 at 37°C. To maintain selection of transfected cells, culture medium for G6D3 cells contained 400 μg ml−1 G418 (Cellgro). Cells were subcultured at 80% confluence.

Fluorescence Studies.

Caco-2 cells were seeded on 18-mm2 glass coverslips at a density of 1.0 × 105 cells cm−2 and grown to confluence. Culture medium was replaced three times a week for 10 to 14 days and 24 h before experiments. Before uptake studies, coverslips were washed twice for 30 min with warm transport buffer, PBS (Life Technologies) containing 0.1 g l−1calcium, pH 7.4 (PBS). Cells were incubated for 15 min at 37°C in PBS containing 50 μM quercetin, quercetin 3-sulfate, or quercetin 4′-glucoside. Transport was halted rapidly by aspiration of buffer and three sequential washings with ice-cold PBS. Cells were fixed for 5 min with 3.5% paraformaldehyde and washed three times. Coverslips were mounted on slides with FluorSave (Calbiochem, La Jolla, CA) and allowed to dry. Cells were examined and images were acquired with Image-Pro Plus (Media Cybernetics, Silver Spring, MD) with a DAGE-MTI CCD100 camera (Michigan City, IN) on a Zeiss Axioplan microscope (Carl Zeiss, Inc., Thornwood, NY).

Cellular Uptake Studies.

For all cellular uptake studies, confluent monolayers of Caco-2 cells, G6D3 cells, and CHO cells were grown on 6-well plastic plates (Corning Costar Corp., Cambridge, MA). Culture medium was replaced three times a week and cells were used 10 to 12 days post seeding. Fresh culture medium was replaced 24 h before transport experiments. One hour before transport experiments, culture medium was aspirated, monolayers were quickly rinsed twice with warm PBS, and monolayers were preincubated twice for 30 min each time in transport buffer. Where applicable, transport inhibitors were included in the final 30-min preincubation. In transport experiments designed to examine sodium dependence, PBS (140 mM Na+) was replaced with sodium-free PBS brought to equal osmolarity with choline chloride (140 mM). Preincubation buffer was aspirated and replaced with 1 ml of transport buffer containing substrates ± inhibitors. Stock solutions of quercetin and quercetin 4′-β-glucoside in ethanol were diluted with transport buffer before transport experiments. The resulting maximum final concentration of ethanol, 0.5%, did not affect the transport of mannitol, a marker of paracellular transport. Nystatin, an ionophore for monovalent cations (Vemuri et al., 1989), was dissolved in dimethyl sulfoxide (final concentration <0.1%) and controls with identical concentrations of dimethyl sulfoxide were examined. All other compounds were dissolved in transport medium. After 4 min, uptake was halted by rapidly aspirating uptake buffer and cells were rinsed three times with ice-cold transport buffer.

For studies with quercetin 4′-β-glucoside, absorbed substrate was extracted from the monolayer with methanol, and extracts were analyzed by reversed phase HPLC analysis on a Millennium HPLC system (Waters Corp., Milford, MA) with a Symmetry C18 column, 3.9 × 150 mm, and a model 996 photodiode array detector. The mobile phase consisted of 35% methanol in 5% acetic acid with a flow rate of 0.9 ml min−1. Quercetin 4′-β-glucoside peak areas were measured at 370 nm. For control studies with [14C]glucose, monolayers were solublized with mild agitation in 1 ml of 50 mM Tris, pH 7.4, containing 2 mM EDTA and 0.1% Triton X-100. Aliquots of the solubilized monolayers were quantified on a Beckman LS 6000SC liquid scintillation system after the addition of ScintiSafe Econo2 (Fisher, Pittsburgh, PA). Transport data are expressed as mean flux ± S.E. ANOVA was used to evaluate differences in flux. A P value <.05 was considered significant.

β-Glucosidase Assay.

Cell-free extracts were prepared from 11-day-old confluent Caco-2 monolayers grown in 100-mm Petri dishes. Cells were washed twice with PBS and scraped into PBS containing 1 mM phenylmethylsulfonyl fluoride and 10 mM 2-mercaptoethanol. The cell suspension was homogenized by fine needle aspiration and centrifuged at 19,000g for 10 min at 4°C. The resulting supernatant was assayed for protein content with the method of Smith et al. (1985) and stored on ice before use. For enzymatic assay, 200 μg of extract protein in phosphate buffer was preincubated for 15 min at 37°C. A final reaction volume of 0.5 ml was obtained by the addition of prewarmed quercetin 4′-glycoside in PBS at time zero. The reaction was halted by the addition of 0.5 ml of ice-cold methanol, followed by centrifugation at 3000g for 10 min. Samples were immediately analyzed by reversed phase HPLC. Apparent kinetic constants were obtained by fitting data to the Henri-Michealis-Menton equation (Segal, 1975) with the solver function in Microsoft Excel 2000.

Results

Fluorescence Studies.

In studies designed to determine whether cellular uptake of quercetin 4′-β-glucoside occurs, we took advantage of the intrinsic fluorescence of the quercetin ring system (Kuo, 1996). In these experiments, we used indirect fluorescent microscopy to examine confluent Caco-2 cell monolayers, grown for 14 days on glass coverslips. In control cells, incubated with buffer alone, no fluorescent signal was observed within the green spectrum (Fig.1A). Cells incubated for 15 min with 50 μM quercetin aglycone, a molecule that crosses the Caco-2 cell monolayer (Walgren et al., 1998), demonstrated cytoplasmic and nuclear staining (Fig. 1B). The negatively charged and highly polar quercetin metabolite quercetin 3-sulfate demonstrated a complete absence of staining (Fig. 1C). In contrast, with our studies that demonstrated a lack of transcellular absorption of quercetin 4′-β-glucoside after apical loading (Walgren et al., 1998), Caco-2 cells that were incubated with 50 μM quercetin 4′-β-glucoside for 15 min demonstrated intracellular staining. This provided direct evidence for absorption of this glucoside across the apical membrane of Caco-2 cells (Fig. 1D).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Cellular uptake of quercetin and quercetin conjugates in Caco-2 cell monolayers. Confluent monolayers, grown for 14 days on glass coverslips, were incubated for 15 min at 37°C with warm transport buffer (A), 50 μM quercetin (B), 50 μM quercetin 3-sulfate (C), or 50 μM quercetin 4′-β-glucoside (D). Transport was halted by aspiration of buffer and cells were washed three times with ice-cold PBS. Coverslips were mounted on slides and examined by indirect fluorescence (original magnification, 100× oil). Scale bar, 10 μm.

Uptake Studies in Caco-2 Monolayers.

To examine the mechanism of transport, we used a method in which methanolic extracts from the monolayers were examined by reversed phase HPLC analysis. This molecularly specific technique demonstrated that the intracellular fluorescence observed after apical exposure to quercetin 4′-β-glucoside was due to uptake of the glucoside, and not the result of metabolites such as the aglycone quercetin or its glucuronides (Walgren et al., 2000). As shown in Fig.2, the observed rate of uptake after exposure to 100 μM quercetin 4′-β-glucoside for 4 min was 2.47 ± 0.12 pmol min−1 cm−2for control (n = 3). This value is well above the minimum detectable amount for this glucoside of 0.001 pmol min−1 cm−2 but is less than 3% of the rate of uptake for 100 μM quercetin aglycone, 100.53 ± 2.80 pmol min−1cm−2 (n = 3). In a previous study, we have shown that the MRP2 inhibitor MK-571 blocked the apical efflux of quercetin 4′-β-glucoside (Walgren et al., 2000). Consistent with this observation, the rate of cellular accumulation of quercetin 4′-β-glucoside increased 3.5-fold to 8.79 ± 1.04 pmol min−1 cm−2(n ≥ 3, P < .05) in the presence of 50 μM MK-571 (Fig. 2). Subsequent experiments with Caco-2 cells were done in the presence of 50 μM MK-571 to enhance the observed rate of uptake by minimizing MRP2-mediated efflux.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Cellular uptake of quercetin 4′-β-glucoside in Caco-2 monolayers. Cells, grown on 6-well plates, were incubated for 4 min with 100 μM quercetin 4′-β-glucoside alone (control) or in the presence of 50 μM MK-571. Cellular uptake of quercetin 4′-β-glucoside was measured by a molecularly specific HPLC method. *P < .05, n ≥ 3.

To test the hypothesis that quercetin 4′-β-glucoside is a substrate for SGLT1, we examined the transport of the glucoside for sodium dependence and for inhibition by both the SGLT1 substrate glucose and the SGLT1 competitive inhibitor phloridzin (Toggenburger et al., 1982). The uptake rate for quercetin 4′-β-glucoside in the absence of sodium was significantly less than that observed in the presence of sodium, 5.30 ± 0.81 versus 12.09 ± 1.37 pmol min−1 cm−2, respectively (n ≥ 5, P < .01; Fig.3A). A similar reduction in the rate of transport was observed in monolayers in which the sodium gradient was uncoupled by treatment with 50 μM nystatin, an ionophore for monovalent cations (Vemuri et al., 1989), 4.92 ± 0.22 pmol min−1 cm−2(n = 5, P < .01). Uptake of quercetin 4′-β-glucoside in the presence of 0.5 mM phloridzin (Fig. 3B) resulted in an approximately 60% reduction in the rate of transport, 3.55 ± 0.36 pmol min−1cm−2 for phloridzin versus 8.79 ± 1.04 pmol min−1 cm−2 for control (n ≥ 9, P < .001), whereas a greater than 70% reduction was observed in the presence of 30 mM glucose, 2.45 ± 0.06 pmol min−1cm−2 (n = 3, P< .01).

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Cellular uptake of quercetin 4′-β-glucoside in Caco-2 monolayers. A, cells treated with 50 μM MK-571 were incubated for 4 min with 100 μM quercetin 4′-β-glucoside in the presence of a normal sodium buffer (control), a sodium-free buffer, or in the presence of 50 μM nystatin in a normal sodium buffer. *P < .01, n ≥ 5. B, cells treated with 50 μM MK-571 were incubated for 4 min with 100 μM quercetin 4′-β-glucoside (control) or with the addition of either 0.5 mM phloridzin (PLZ) or 30 mM glucose. **P < .001,n ≥ 9; †P < .01,n = 3.

Uptake Studies in SGLT1-Transfected G6D3 Cells.

G6D3 cells, a CHO cell line that has been stably transfected with SGLT1 (Lin et al., 1998), were used to examine the transport of quercetin 4′-β-glucoside. In our initial experiments with these cells, we examined the uptake of quercetin 4′-β-glucoside alone or in the presence of 30 mM glucose. A low rate of cellular uptake was observed in the presence of glucose, 0.30 ± 0.04 pmol min−1 cm−2, or about one-quarter that observed in the control treatment, 1.14 ± 0.20 pmol min−1 cm−2(n ≥ 6, P < .001; Fig.4). While we were doing these experiments, Barnouin et al. (1998) reported finding expression of the hamster homolog of MRP1 (Mrp1) in parental CHO-K1 cells. Because similar substrate specificities have been found for MRP1 and MRP2 (König et al., 1999), we also examined the influence of 50 μM MK-571 on the uptake of quercetin 4′-β-glucoside in these SGLT1-transfected CHO cells. As seen in Fig. 4, the rate of uptake was almost 6.5 times greater with the MRP inhibitor MK-571, 7.35 ± 0.55 pmol min−1 cm−2(n ≥ 15, P < .0001). Next, we examined uptake of quercetin 4′-β-glucoside in G6D3 cells for inhibition by phloridzin and glucose. In G6D3 cells, the presence of either 0.5 mM phloridzin or 30 mM glucose reduced the uptake of quercetin 4′-β-glucoside by approximately one-half, 3.75 ± 0.25 pmol min−1 cm−2 for phloridzin and 3.83 ± 0.27 for glucose versus 7.35 ± 0.55 pmol min−1 cm−2 for control (n ≥ 14, P < .0001; Fig. 4), analogous to the findings in Caco-2 cells (Fig. 3).

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Cellular uptake of quercetin 4′-β-glucoside in G6D3 cells. G6D3 cells were incubated for 4 min with 100 μM quercetin 4′-β-glucoside alone (control) or in the presence of 30 mM glucose, 50 μM MK-571, 50 μM MK-571 and 0.5 mM phloridzin (PLZ), or 50 μM MK-571 and 30 mM glucose. *P< .001, significantly lower than control, n ≥ 6; **P < .0001, significantly greater than control, n ≥ 15;†P < .0001, significantly lower than in the presence of MK-571 alone, n ≥ 14.

To further test our hypothesis, we compared the transport of [14C]glucose and quercetin 4′-β- glucoside in both G6D3 cells and parental CHO cells. In addition, we examined their transport for sodium dependence with a sodium-free transport buffer (Fig. 5, A and B). For examining quercetin 4′-β-glucoside transport we included, as in experiments with the Caco-2 cells, pretreatment with 50 μM MK-571. Transport rates for both substrates were significantly greater in the G6D3 cells than those observed in the CHO cells (P < .0001). In the CHO cells, the rate of transport for both [14C]glucose and quercetin 4′-β-glucoside was unaltered in the absence of sodium, 24.2 ± 0.7 versus 21.5 ± 1.9 pmol min−1 cm−2for glucose and 4.90 ± 0.30 versus 4.70 ± 0.60 pmol min−1 cm−2 for quercetin 4′-β-glucoside. In G6D3 cells, transport rates for both substrates were significantly reduced in the absence of sodium, 43.3 ± 3.8 versus 28.7 ± 1.9 pmol min−1cm−2 for glucose and 19.4 ± 1.1 versus 11.6 ± 0.5 pmol min−1cm−2 for quercetin 4′-β-glucoside (n = 6, P < .001).

Figure 5
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5

Sodium-dependent uptake of [14C]glucose and quercetin 4′-β-glucoside in CHO-K1 and G6D3 cells. Both G6D3 cells and CHO cells were incubated with 100 μM [14C]glucose (A) or 100 μM quercetin 4′-β-glucoside (B) for 4 min in either a sodium (dark bars) or sodium free (light bars) buffer. *P < .001, n = 6, significantly less than uptake in G6D3 cells in the presence of sodium; †P < .0001,n ≥ 3, significantly less than uptake uptake in G6D3 cells in the presence of sodium.

β-Glucosidase Assay.

The ability of Caco-2 cells to hydrolyze quercetin 4′-glucoside to quercetin aglycone was examined in cell-free extracts. The reaction was linear over 1 h (Fig.6A) and recovery was >99%. No activity was observed in heat-inactivated cell extracts (data not shown). The β-glucosidase activity at various concentrations was measured based on the formation of the aglycone and used to determine apparent kinetic constants (Fig. 6B). The cell extract demonstrated an apparentKm for the hydrolysis of quercetin 4′-glucoside of 78.4 μM and a Vmaxof 0.27 mU mg of protein−1 (enzymatic unit of activity where one unit is defined as 1 μmol of product formed per minute at 37°C).

Figure 6
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6

Hydrolysis of quercetin 4′-β-glucoside to quercetin aglycone was examined in cell-free extracts from Caco-2 cells. A, prewarmed cell-free extracts were incubated with 30 μM quercetin 4′-β-glucoside for various times at 37°C. B, prewarmed cell free extracts were incubated with various concentration of quercetin 4′-β-glucoside for 15 min at 37°C. Points represent mean ± S.E. of triplicate determinations.

Discussion

To examine the relative absorption of dietary flavonoids and to gain insight into the mechanisms governing their absorption we have used human Caco-2 cell monolayers, a widely accepted model of human intestinal absorption (Artursson and Karlsson, 1991; Yee, 1997). In our previous studies, we have demonstrated that although the minor dietary flavonoid quercetin aglycone is well absorbed, the major dietary flavonoid quercetin 4′-β-glucoside is not (Walgren et al., 1998). This finding was in sharp contrast to indirect evidence that this glucoside is absorbed via the active intestinal glucose transporter (Hollman et al., 1995; Gee et al., 1998). Further studies with the Caco-2 cell model have demonstrated that quercetin 4′-β-glucoside is, in fact, effluxed by the apically expressed MRP2 (Walgren et al., 2000). Although these studies did not provide evidence for absorption of quercetin 4′-β-glucoside, MRP2-dependent efflux may have prevented detection of absorption, including possible transport by the sodium-dependent glucose transporter SGLT1.

The results from this study demonstrate that quercetin 4′-β-glucoside is indeed transported by SGLT1. With the intrinsic fluorescence of quercetin and its derivatives, we have been able to examine the uptake of these compounds across the apical membrane of Caco-2 cells grown on glass coverslips. Consistent with our transcellular absorption studies, clear evidence was obtained for the uptake of quercetin aglycone. Despite the lack of transcellular absorption observed in our previous studies (Walgren et al., 1998), cells incubated with quercetin 4′-β-glucoside also demonstrated an intracellular staining, supporting absorption of the glucoside across the apical membrane (Fig.1D). Transport of the intact and unaltered glucoside was confirmed by HPLC analysis of extracts from Caco-2 monolayers incubated with quercetin 4′-β-glucoside. As predicted based on the subcellular localization of MRP2 to the apical membrane of Caco-2 cells (Walgren et al., 2000), the cellular uptake of the glucoside was enhanced in the presence of the MRP2 inhibitor MK-571 (Fig. 2). We have demonstrated that the uptake of quercetin 4′-β-glucoside across the apical membrane of Caco-2 cells is sodium-dependent and is inhibited by both glucose, a substrate of SGLT1, and phloridzin, a competitive inhibitor of SGLT1 (Fig. 3).

As additional evidence for transport of quercetin 4′-β-glucoside by SGLT1 we have examined transport of the glucoside in G6D3 cells, a CHO cell line that has been stably transfected with rabbit SGLT1 (Lin et al., 1998). Uptake of quercetin 4′-β-glucoside in G6D3 cells was inhibited by both glucose and phloridzin. The unexpected presence of the MRP1 efflux pump also limited cellular absorption in this cell line. However, the use of MK-571 to inhibit this pump enabled us to selectively examine SGLT1-dependent transport (Fig. 4). Furthermore, the observed transport rate for quercetin 4′-β-glucoside uptake was greater in transfected G6D3 cells than in parental CHO-K1 cells, and the transport demonstrated sodium dependence in the G6D3 cells but not in the CHO-K1 cells (Fig. 5).

Based on our accumulated results, the intestinal absorption of dietary flavonoids is becoming more clearly defined (Fig.7). The major dietary flavonoid, quercetin 4′-β-glucoside, is absorbed across the brush-border membrane by SGLT1. MRP2, also localized to the apical membrane, is capable of effluxing quercetin 4′-β-glucoside and effectively opposing absorption and intracellular accumulation. However, upon gaining access to the cytosol, quercetin 4′-β-glucoside may undergo metabolism such as hydrolysis, yielding quercetin aglycone. Hydrolysis by a broad specificity β-glucosidase is supported by our results obtained with extracts from Caco-2 cells (Fig. 6) and by the recent identification of a similar enzymatic activity within the human intestine (Day et al., 1998). Quercetin aglycone may then undergo further metabolism (Boulton et al., 1998; Crespy et al., 1999; Walle et al., 1999b) or it may cross the basolateral membrane, resulting in absorption (Walgren et al., 1998).

Figure 7
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 7

Model of quercetin 4′-β-glucoside absorption in the enterocyte. Quercetin 4′-β-glucoside (Q4′G), the predominant dietary form of quercetin, is actively absorbed across the apical membrane by SGLT1 and is actively effluxed across the apical membrane by MRP2. Although present in the cytosol, quercetin 4′-β-glucoside is unable to exit the cell at the basolateral membrane. However, it is able to enter the cell across the basolateral membrane, suggesting the presence of an unidentified transporter. Once within the cell, the glucoside may undergo metabolism such as hydrolysis to produce quercetin aglycone (Q).

Although this study has revealed the interplay in the flux of quercetin 4′-β-glucoside across the apical membrane of Caco-2 cells between the inwardly directed SGLT1 and the outwardly directed MRP2, it is still not clear why transcellular absorption does not occur. In fact, even in the presence of the MRP2 inhibitor MK-571, transepithelial absorption of the glucoside has been detected only after apical loading with very high concentrations of the glucoside. Even then, only a very minute level of transport was observed, suggesting the presence of a saturable, intracellularly directed transporter at the basolateral membrane. In contrast, after basolateral loading, the rate-limiting step in the transcellular flux of quercetin 4′-β-glucoside appears to be transport by MRP2 on the apical side (Walgren et al., 2000).

Interestingly, a similar multitransporter system has recently been described within the renal proximal tubule. In proximal tubule cells, organic anions enter the cell across the basolateral membrane via the organic anion transporter OAT, or via another as yet unidentified transporter. Once within the cell, they are subsequently effluxed across the apical membrane by MRP2 or potentially by a second unidentified transporter (Masereeuw et al., 1999). We have been able to rule out the possibility that quercetin 4′-β-glucoside crosses the basolateral membrane of the Caco-2 cell via a sodium-dependent process because the transcellular efflux of this glucoside is not reduced in the absence of sodium (R. A. Walgren and T. Walle, unpublished data).

Absorption of the flavonoid glucosides, across the apical membrane, appears to be governed by a balance between uptake by SGLT1 and efflux by MRP2. Although this balance may favor efflux by MRP2 for quercetin 4′-β-glucoside and genistein-7-glucoside (Walle et al., 1999a), it may be shifted to favor absorption by SGLT1 for other glucosides. For example, a recent study demonstrated clear absorption of the flavonoid cyanidine 3-β-glucoside in the intact rat (Tsuda et al., 1999). It may be that this flavonoid, which carries a positive charge on the aglycone moiety, is not a substrate for the MRP2 efflux pump and, hence, is efficiently absorbed via SGLT1. Aside from flavonoids, a normal diet contains a number of other glucosides, including β-glucoside derivatives of niacin in wheat bran and pyridoxine 5′-β-glucose, the major dietary form of vitamin B6 (Gregory, 1998). A number of therapeutic agents also are used orally as glycosides, including the aminoglycoside antibiotic neomycin, which is unabsorbed, and the orally absorbed cardiac glycoside digoxin. It is interesting to note that although attempts have been made to improve the intestinal absorption of peptides and nucletide analogs by glycosylation with glucose (Nomoto et al., 1998; Mizuma et al., 1999), the addition of glucose may not only produce a substrate for SGLT1 but also a substrate for MRP2. This possibility, which is of great relevance to new drug development, will require further studies.

A lack of intestinal absorption of the flavonoid glucosides does not imply a lack of biological effects from these compounds in humans. It has long been argued that enzymes from the colonic microflora can hydrolyze flavonoid glucosides (Griffiths and Barrow 1972; Bokkenheuser et al., 1987). In addition, a recent study in ileostomy patients demonstrated that the dietary quercetin glucosides are completely hydrolyzed before the colon,2potentially suggesting a nonbacterial source of β-glucosidase in the human intestine. As shown by Day et al. (1998) and confirmed in this study (Fig. 6), enterocytes have the ability to hydrolyze absorbed quercetin 4′-β-glucoside within the cytosol. The fate of the resulting quercetin aglycone may include transport out of the epithelial cell (Walgren et al., 1998) or metabolism by a variety of enzymes (Boulton et al., 1998; Crespy et al., 1999; Walle et al., 1999b), with presently unknown consequences.

In summary, this study demonstrates for the first time that quercetin 4′-β-glucoside, the most abundant dietary flavonoid, is transported by SGLT1 across the apical membrane of enterocytes. However, its transcellular absorption is limited by MRP2-mediated efflux across the apical membrane as well as by an unknown transporter on the basolateral membrane.

Acknowledgment

We thank Dr. Steven A. Rosenzweig for critical discussions.

Footnotes

  • Send reprint requests to: Thomas Walle, Ph.D., Medical University of South Carolina, Department of Cell and Molecular Pharmacology and Experimental Therapeutics, 173 Ashley Ave., P.O. Box 250505, Charleston, SC 29425. E-mail: wallet{at}musc.edu

  • ↵1 This study was supported by National Institutes of Health Grant GM55561.

  • ↵2 T. Walle, Y. Otake, A. L. Jones, U. K. Walle and F. A. Wilson (2000) Bioavailability of the flavonoid quercetin in ileostomy patients. Poster abstract no. 1278, Americal Association for Cancer Research 91st Annual Meeting.

  • Abbreviations:
    SGLT1
    sodium-dependent d-glucose cotransporter
    MRP
    multidrug resistance-associated protein
    CHO
    Chinese hamster ovary
    MEM
    miminum essential medium
    • Received March 6, 2000.
    • Accepted May 5, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Artursson P,
    2. Karlsson J
    (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal (Caco-2) cells. Biochem Biophys Res Commun 175:880–885.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Aziz AA,
    2. Edwards CA,
    3. Lean MEJ,
    4. Crozier A
    (1999) Absorption and excretion of conjugated flavonols, including quercetin-4′-O-β-glucoside and isorhamnetin-4′-O-β-glucoside by human volunteers after the consumption of onions. Free Radic Res 29:257–269.
  3. ↵
    1. Barnouin K,
    2. Leier I,
    3. Jedlitschky G,
    4. Pourtier-Manzanedo A,
    5. König J,
    6. Lehmann WD,
    7. Keppler D
    (1998) Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer 77:201–209.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Blais A,
    2. Bissonnette P,
    3. Berteloot A
    (1987) Common characteristics for Na+-dependent sugar transport in Caco-2 cells and human fetal colon. J Membr Biol 99:113–125.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bokkenheuser VD,
    2. Shackleton CHL,
    3. Winter J
    (1987) Hydrolysis of dietary glycosides by strains of intestinal Bacteroides from humans. Biochem J 248:953–956.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Boulton DW,
    2. Walle UK,
    3. Walle T
    (1998) Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol 50:243–249.
    OpenUrlPubMed
  7. ↵
    1. Crespy V,
    2. Morand C,
    3. Manach C,
    4. Besson C,
    5. Demigne C,
    6. Remesy C
    (1999) Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am J Physiol 277:G120–G126.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Day AJ,
    2. DuPont MS,
    3. Ridley S,
    4. Rhodes M,
    5. Rhodes MJC,
    6. Morgan MRA,
    7. Williamson G
    (1998) Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucosidase activity. FEBS Lett 436:71–75.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Gee JM,
    2. DuPont MS,
    3. Rhodes MJC,
    4. Johnson IT
    (1998) Quercetin glucosides interact with the intestinal glucose transport pathway. Free Radic Biol Med 25:19–25.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gregory JF III
    (1998) Nutritional properties and significance of vitamin glycosides. Annu Rev Nutr 18:277–296.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Griffiths LA,
    2. Barrow A
    (1972) Metabolism of flavonoid compounds in germ-free rats. Biochem J 130:1161–1162.
    OpenUrlFREE Full Text
  12. ↵
    1. Gugler R,
    2. Leschik M,
    3. Dengler HJ
    (1975) Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 9:229–234.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Hertog MGL,
    2. Feskens EJM,
    3. Hollman PCH,
    4. Katan MB,
    5. Kromhout D
    (1993) Dietary antioxidant flavonoids and risk of coronary heart disease. Lancet 342:1007–1011.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Hollman PCH,
    2. van Trijp JMP,
    3. Buysman MNCP,
    4. vd Gaag MS,
    5. Mengelers MJB,
    6. de Vries JHM,
    7. Katan MB
    (1997) Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett 418:152–156.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hollman PCH,
    2. de Vries JHM,
    3. van Leeuwen SD,
    4. Mengelers MJB,
    5. Katan MB
    (1995) Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 62:1276–1282.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. König J,
    2. Nies AT,
    3. Cui Y,
    4. Leier I,
    5. Keppler D
    (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377–394.
    OpenUrlPubMed
  17. ↵
    1. Kuo SM
    (1996) Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett 110:41–48.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Lin JT,
    2. Kormanec J,
    3. Wehner F,
    4. Wielert-Badt S,
    5. Kinne RKH
    (1998) High-level expression of Na+/D-glucose cotransporter (SGLT1) in a stably transfected Chinese hamster ovary cell line. Biochim Biophys Acta 1373:309–320.
    OpenUrlPubMed
  19. ↵
    1. Manach C,
    2. Morand C,
    3. Crespy V,
    4. Demingné C,
    5. Texier O,
    6. Régérat F,
    7. Rémésy C
    (1998) Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 426:331–336.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Masereeuw R,
    2. Moons MM,
    3. Toomey BH,
    4. Russel FGM,
    5. Miller DS
    (1999) Active Lucifer yellow secretion in renal proximal tubule: Evidence for organic anion transport system crossover. J Pharmacol Exp Ther 289:1104–1111.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Mizuma T,
    2. Masubuchi S,
    3. Awazu S
    (1999) Intestinal absorption of acyclovir β-glucoside: Comparative study with acyclovir, guanosine, and kinetin β-glucoside. Pharm Res 16:69–73.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Nomoto M,
    2. Yamada K,
    3. Haga M,
    4. Hayashi M
    (1998) Improvement of intestinal absorption of peptide drugs by glycosylation: Transport of tetra peptide by the sodium ion-dependent D-glucose transporter. J Pharm Sci 87:326–332.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Segal IH
    (1975) Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems (John Wiley & Sons, New York), pp 19–21.
  24. ↵
    1. Smith PK,
    2. Krohn RI,
    3. Hermanson GT,
    4. Malia AK,
    5. Gartner FH,
    6. Provenzano MD,
    7. Fujimoto EK,
    8. Goeke NM,
    9. Olson BJ,
    10. Klenk DC
    (1985) Measurement of protein using bicinchonic acid [published erratum appears in Anal Biochem (1987) 163:279]. Anal Biochem 150:76–85.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Toggenburger G,
    2. Kessler M,
    3. Semenza G
    (1982) Phlorizin as a probe of the small-intestinal Na+, D-glucose cotransporter. A model. Biochim Biophys Acta 688:557–571.
    OpenUrlPubMed
  26. ↵
    1. Tsuda T,
    2. Horio F,
    3. Osawa T
    (1999) Absorption and metabolism of cyaniding 3-O-β-D-glucoside in rats. FEBS Lett 449:179–182.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Vemuri R,
    2. Longoni S,
    3. Philipson KD
    (1989) Oubain treatment of cardiac cells induces enhanced Na+-Ca2+ exchange activity. Am J Physiol 256:C1273–C1276.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Walgren RA,
    2. Karnaky KJ, Jr,
    3. Lindenmayer GE,
    4. Walle T
    (2000) Efflux of dietary flavonoid quercetin 4′-β-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 294:830–836.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Walgren RA,
    2. Walle UK,
    3. Walle T
    (1998) Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol 55:1721–1727.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Walle UK,
    2. French KL,
    3. Walgren RA,
    4. Walle T
    (1999a) Transport of genistein-7-glucoside by human intestinal Caco-2 cells: Potential role for MRP2. Res Commun Mol Pathol Pharmacol 103:45–56.
    OpenUrlPubMed
  31. ↵
    1. Walle UK,
    2. Galijatovic A,
    3. Walle T
    (1999b) Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol 58:431–438.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Yee S
    (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—fact or myth. Pharm Res 14:763–766.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 294 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 294, Issue 3
1 Sep 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cellular Uptake of Dietary Flavonoid Quercetin 4′-β-Glucoside by Sodium-Dependent Glucose Transporter SGLT1
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Cellular Uptake of Dietary Flavonoid Quercetin 4′-β-Glucoside by Sodium-Dependent Glucose Transporter SGLT1

Richard A. Walgren, Jiann-Trzuo Lin, Rolf K.-H. Kinne and Thomas Walle
Journal of Pharmacology and Experimental Therapeutics September 1, 2000, 294 (3) 837-843;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Cellular Uptake of Dietary Flavonoid Quercetin 4′-β-Glucoside by Sodium-Dependent Glucose Transporter SGLT1

Richard A. Walgren, Jiann-Trzuo Lin, Rolf K.-H. Kinne and Thomas Walle
Journal of Pharmacology and Experimental Therapeutics September 1, 2000, 294 (3) 837-843;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Transport Is Not Rate-Limiting in Morphine Glucuronidation in the Single-Pass Perfused Rat Liver Preparation
  • Enhanced Hepatic Uptake and Bioactivity of Type α1(I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol
  • Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Show more ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics